With this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.

AMD's technology will also be used to boost Absci's drug discovery workload, including the company's de novo antibody design ...

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set to transform therapeutic development. By ...

Celltrion targets innovative drug development with new ADC and antibody candidates Celltrion aims for growth by venturing ...

Research led by Brock University has found a possible cure for lung diseases typically found in older adults, such as pulmonary fibrosis. The findings are published in the journal Aging Cell.

Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop ...

Under the agreement, UCB gains a non-exclusive license to leverage XtalFold for the discovery and engineering of biologics.

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation and a part of Danaher Corporation, has ...

Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- InveniAI LLC, a global leader in the application of artificial intelligence (AI), machine learning (ML), and generative AI tools to revolutionize drug discovery and .